CY1121863T1 - Δυνητικα αντιγραφικος κυτομεγαλοϊος ως εμβολιο για cmv - Google Patents
Δυνητικα αντιγραφικος κυτομεγαλοϊος ως εμβολιο για cmvInfo
- Publication number
- CY1121863T1 CY1121863T1 CY20191100836T CY191100836T CY1121863T1 CY 1121863 T1 CY1121863 T1 CY 1121863T1 CY 20191100836 T CY20191100836 T CY 20191100836T CY 191100836 T CY191100836 T CY 191100836T CY 1121863 T1 CY1121863 T1 CY 1121863T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cmv
- present
- infection
- cytomegaloya
- vaccine
- Prior art date
Links
- 230000003362 replicative effect Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 241000701022 Cytomegalovirus Species 0.000 abstract 7
- 230000002950 deficient Effects 0.000 abstract 3
- 230000010076 replication Effects 0.000 abstract 3
- 206010011831 Cytomegalovirus infection Diseases 0.000 abstract 1
- 206010042566 Superinfection Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000007420 reactivation Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000029812 viral genome replication Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/04—Varicella-zoster virus
- C07K14/045—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η παρούσα εφεύρεση αφορά σε μεθόδους διέγερσης ανοσοαπόκρισης σε κυτομεγαλοϊό (CMV) χρησιμοποιώντας γενετικώς τροποποιημένο CMV που είναι δυνητικά ελαττωματικός αντιγραφής. Οι μέθοδοι της εφεύρεσης μπορεί να χρησιμοποιηθούν για να θεραπεύεται ή/και να αποτρέπεται πρωτογενής CMV μόλυνση, μόλυνση λόγω επανενεργοποίησης ενός λανθάνοντος CMV και υπερ-μόλυνση ενός διαφορετικού στελέχους του CMV που είχε προηγουμένης αντιμετωπιστεί. Η παρούσα εφεύρεση επίσης αφορά σε ελαττωματικό αντιγραφής CMV που έχει ανασυνδυαστικώς μεταβληθεί για να επιτρέπει εξωτερικό έλεγχο ιικής αντιγραφής. Συνθέσεις που περιλαμβάνουν τον ελαττωματικό αντιγραφής CMV επίσης αντιμετωπίζονται με την παρούσα εφεύρεση.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161532667P | 2011-09-09 | 2011-09-09 | |
| PCT/US2012/053599 WO2013036465A2 (en) | 2011-09-09 | 2012-09-04 | A conditional replicating cytomegalovirus as a vaccine for cmv |
| EP12830346.8A EP2753364B1 (en) | 2011-09-09 | 2012-09-04 | A conditional replicating cytomegalovirus as a vaccine for cmv |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121863T1 true CY1121863T1 (el) | 2020-07-31 |
Family
ID=47832753
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100780T CY1119107T1 (el) | 2011-09-09 | 2017-07-20 | Δυνητικα αντιγραφικος κυτομεγαλοϊος ως εμβολιο για cmv |
| CY20191100836T CY1121863T1 (el) | 2011-09-09 | 2019-08-06 | Δυνητικα αντιγραφικος κυτομεγαλοϊος ως εμβολιο για cmv |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100780T CY1119107T1 (el) | 2011-09-09 | 2017-07-20 | Δυνητικα αντιγραφικος κυτομεγαλοϊος ως εμβολιο για cmv |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9546355B2 (el) |
| EP (3) | EP3251700B1 (el) |
| JP (1) | JP5926804B2 (el) |
| KR (1) | KR101668163B1 (el) |
| CN (1) | CN103889462B (el) |
| AR (1) | AR087772A1 (el) |
| AU (1) | AU2012304783B2 (el) |
| BR (1) | BR112014005404A8 (el) |
| CA (1) | CA2846870C (el) |
| CL (1) | CL2014000541A1 (el) |
| CY (2) | CY1119107T1 (el) |
| DK (2) | DK2753364T3 (el) |
| ES (2) | ES2633190T3 (el) |
| HR (2) | HRP20171120T1 (el) |
| HU (2) | HUE035322T2 (el) |
| IL (1) | IL231272B (el) |
| IN (1) | IN2014CN01809A (el) |
| LT (2) | LT3251700T (el) |
| ME (2) | ME03488B (el) |
| MX (1) | MX353037B (el) |
| NZ (1) | NZ622156A (el) |
| PE (1) | PE20141525A1 (el) |
| PL (2) | PL3251700T3 (el) |
| PT (2) | PT3251700T (el) |
| RS (2) | RS58891B1 (el) |
| RU (2) | RU2670012C1 (el) |
| SG (1) | SG11201400419YA (el) |
| SI (2) | SI2753364T1 (el) |
| TR (1) | TR201910644T4 (el) |
| TW (1) | TWI570240B (el) |
| UA (1) | UA114896C2 (el) |
| WO (1) | WO2013036465A2 (el) |
| ZA (1) | ZA201401708B (el) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016501023A (ja) * | 2012-12-04 | 2016-01-18 | メルク・シャープ・アンド・ドーム・コーポレーションＭ | 条件付き複製ウイルスベクター |
| MX2015016978A (es) * | 2013-06-10 | 2016-04-25 | Merck Sharp & Dohme | Proteinas de union a antigeno neutralizantes de citomegalovirus. |
| WO2016011293A1 (en) | 2014-07-16 | 2016-01-21 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
| EP3048114A1 (en) * | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
| WO2017070613A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| WO2018075980A1 (en) | 2016-10-21 | 2018-04-26 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| BR112020008482A8 (pt) * | 2017-11-01 | 2023-01-31 | Merck Sharp & Dohme | Composto leuco |
| US20210047626A1 (en) * | 2018-04-24 | 2021-02-18 | Merck Sharp & Dohme Corp. | Scalable chromatography process for purification of human cytomegalovirus |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| US20220090005A1 (en) | 2019-01-03 | 2022-03-24 | Merck Sharp & Dohme Corp. | Supplemented Serum-Containing Culture Medium for Enhanced Arpe-19 Growth and Human Cytomegalovirus Vaccine Production |
| CA3146798A1 (en) * | 2019-07-12 | 2021-01-21 | Kobenhavns Universitet | Fusion toxin proteins for treatment of diseases related to cmv infections |
| US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| CN112481222B (zh) * | 2020-11-30 | 2024-01-02 | 中国医学科学院医学生物学研究所 | 一种条件复制型重组单纯疱疹病毒、疫苗及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1150712T3 (da) * | 1999-02-05 | 2009-02-02 | Merck & Co Inc | Vaccineformuleringer mod human papillomavirus |
| ES2429338T3 (es) | 2002-12-23 | 2013-11-14 | Vical Incorporated | Vacuna basada en polinucleótidos optimizados por codones contra infección por citomegalovirus humano |
| US20060110406A1 (en) * | 2003-02-25 | 2006-05-25 | Medimmune Vaccines, Inc. | Refrigerator-temperature stable influenza vaccine compositions |
| WO2004076645A2 (en) * | 2003-02-27 | 2004-09-10 | University Of Massachusetts | Compositions and methods for cytomegalovirus treatment |
| NZ560929A (en) * | 2005-02-18 | 2009-12-24 | Novartis Vaccines & Diagnostic | Immunogens from uropathogenic escherichia coli |
| EP2037959B1 (en) * | 2006-06-07 | 2016-01-27 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| US8173792B2 (en) * | 2007-02-09 | 2012-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells using synthetic small molecules |
| US9439960B2 (en) * | 2007-10-10 | 2016-09-13 | The Trustees Of Princeton University | Cytomegalovirus vaccines and methods of production |
| US8530636B2 (en) * | 2008-05-07 | 2013-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells in vivo using synthetic small molecules |
-
2012
- 2012-09-03 TW TW101132064A patent/TWI570240B/zh active
- 2012-09-04 RU RU2017102888A patent/RU2670012C1/ru active
- 2012-09-04 UA UAA201403638A patent/UA114896C2/uk unknown
- 2012-09-04 EP EP17171651.7A patent/EP3251700B1/en active Active
- 2012-09-04 PT PT17171651T patent/PT3251700T/pt unknown
- 2012-09-04 DK DK12830346.8T patent/DK2753364T3/en active
- 2012-09-04 NZ NZ622156A patent/NZ622156A/en unknown
- 2012-09-04 ME MEP-2019-176A patent/ME03488B/me unknown
- 2012-09-04 EP EP19175776.4A patent/EP3572096A1/en active Pending
- 2012-09-04 DK DK17171651.7T patent/DK3251700T3/da active
- 2012-09-04 RU RU2014113921A patent/RU2611198C2/ru active
- 2012-09-04 JP JP2014529788A patent/JP5926804B2/ja active Active
- 2012-09-04 ES ES12830346.8T patent/ES2633190T3/es active Active
- 2012-09-04 ES ES17171651T patent/ES2737852T3/es active Active
- 2012-09-04 CA CA2846870A patent/CA2846870C/en active Active
- 2012-09-04 IN IN1809CHN2014 patent/IN2014CN01809A/en unknown
- 2012-09-04 PT PT128303468T patent/PT2753364T/pt unknown
- 2012-09-04 CN CN201280053360.7A patent/CN103889462B/zh active Active
- 2012-09-04 WO PCT/US2012/053599 patent/WO2013036465A2/en active Application Filing
- 2012-09-04 HU HUE12830346A patent/HUE035322T2/en unknown
- 2012-09-04 ME MEP-2017-157A patent/ME02831B/me unknown
- 2012-09-04 PL PL17171651T patent/PL3251700T3/pl unknown
- 2012-09-04 LT LTEP17171651.7T patent/LT3251700T/lt unknown
- 2012-09-04 KR KR1020147008959A patent/KR101668163B1/ko active IP Right Grant
- 2012-09-04 PE PE2014000323A patent/PE20141525A1/es active IP Right Grant
- 2012-09-04 BR BR112014005404A patent/BR112014005404A8/pt not_active Application Discontinuation
- 2012-09-04 US US14/343,637 patent/US9546355B2/en active Active
- 2012-09-04 SI SI201231003T patent/SI2753364T1/sl unknown
- 2012-09-04 RS RS20190753A patent/RS58891B1/sr unknown
- 2012-09-04 RS RS20170715A patent/RS56261B1/sr unknown
- 2012-09-04 MX MX2014002815A patent/MX353037B/es active IP Right Grant
- 2012-09-04 TR TR2019/10644T patent/TR201910644T4/tr unknown
- 2012-09-04 SG SG11201400419YA patent/SG11201400419YA/en unknown
- 2012-09-04 AR ARP120103253A patent/AR087772A1/es active IP Right Grant
- 2012-09-04 HU HUE17171651A patent/HUE045115T2/hu unknown
- 2012-09-04 SI SI201231634T patent/SI3251700T1/sl unknown
- 2012-09-04 EP EP12830346.8A patent/EP2753364B1/en active Active
- 2012-09-04 AU AU2012304783A patent/AU2012304783B2/en active Active
- 2012-09-04 LT LTEP12830346.8T patent/LT2753364T/lt unknown
- 2012-09-04 PL PL12830346T patent/PL2753364T3/pl unknown
-
2014
- 2014-03-02 IL IL231272A patent/IL231272B/en active IP Right Grant
- 2014-03-06 CL CL2014000541A patent/CL2014000541A1/es unknown
- 2014-03-07 ZA ZA2014/01708A patent/ZA201401708B/en unknown
-
2017
- 2017-07-20 HR HRP20171120TT patent/HRP20171120T1/hr unknown
- 2017-07-20 CY CY20171100780T patent/CY1119107T1/el unknown
-
2019
- 2019-06-18 HR HRP20191111TT patent/HRP20191111T1/hr unknown
- 2019-08-06 CY CY20191100836T patent/CY1121863T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121863T1 (el) | Δυνητικα αντιγραφικος κυτομεγαλοϊος ως εμβολιο για cmv | |
| CY1125387T1 (el) | Αντιγονα, διαβιβαστες, συνθεσεις του ιου της ανθρωπινης ανοσοανεπαρκειας, και μεθοδοι χρησης τους | |
| PH12017550022A1 (en) | Phosphoramidates for the treatment of hepatitis b virus | |
| CY1120987T1 (el) | Cmv γλυκοπρωτεϊνες και ανασυνδυασμενοι φορεις | |
| CY1123774T1 (el) | Στελεχη shigella me υπερφυσαλιδωση | |
| MX2018008413A (es) | Virus oncolitico modificado. | |
| MX2020013153A (es) | Metodos y composiciones para inducir inmunidad protectora contra la infeccion por virus de inmunodeficiencia humana. | |
| PH12016501631A1 (en) | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
| EA201790532A1 (ru) | Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса | |
| CY1125338T1 (el) | Λιποκατιονικα δενδριμερη και χρησεις εξ αυτων | |
| CY1123031T1 (el) | Ρυθμιστες της δραστικοτητας του συμπληρωματος | |
| MA39717A (fr) | Procédés et compositions pour accroître le rapport des lymphocytes t effecteurs aux lymphocytes t régulateurs | |
| CY1123654T1 (el) | Αποδεσμευση πρωτεϊνης me βαση βακτηρια | |
| EA201790167A1 (ru) | Цитомегаловирус человека, содержащий экзогенные антигены | |
| MX2016013362A (es) | Nuevos compuestos macrociclicos. | |
| TN2015000186A1 (en) | N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group | |
| PH12018501750A1 (en) | Porcine reproductive and respiratory syndrome vaccine virus | |
| ECSP14013300A (es) | Un citomegalovirus de replicacion condicionada como vacuna contra el cmv | |
| WO2018175580A3 (en) | Development of an alternative modified live influenza b virus vaccine | |
| MX2021015236A (es) | Métodos para el tratamiento contra infecciones virales. | |
| CY1121075T1 (el) | Μεθοδοι για τη παραγωγη σωματιδιων ρεπλικονιων bunya virus | |
| EP4061416A4 (en) | POWASSAN VIRUS ANTIGENS AND RELATED COMPOSITIONS AND USES THEREOF FOR VACCINATION AND TREATING PATIENTS | |
| BR112013007308A2 (pt) | vacina | |
| MX2021015938A (es) | Virus para vacuna contra el síndrome respiratorio y reproductivo porcino. | |
| EA202191862A2 (ru) | Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения |